CD19 and Sepsis: Thirty-nine patients were enrolled in two cohorts (B-ALL, n = 17, LBCL, n = 22); 38 patients received the CD19-22.BB.z-CAR infusion while one patient with LBCL died during lymphodepletion due to progressive disease and sepsis (Extended Data Fig. 3).